Fontolizumab
Based on 1 Customer Validation
Fontolizumab (HuZAF) is a human monoclonal antibody targeting interferon γ (IFN-γ). Fontolizumab binds specifically and with high affinity to secreted IFN-γ, neutralizes its activity, blocks receptor binding, and inhibits downstream signal transduction and the expression of IFNγ-responsive genes. Fontolizumab reduces serum C-reactive protein levels, inhibits the expression of IL-1α, IL-1β and IL-12Rβ2, and decreases the number of IFNγ-producing T cells in activated peripheral blood mononuclear cells. Fontolizumab can be used in research related to Crohn's disease.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 97.18%
- CAS No.: 326859-36-3
- 분자량:144.8 kDa
-
보관:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
|
IFN-γ |
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
신청
ELISA, FACS, Functional assay
Product Details
-
CAS No. 326859-36-3
-
Accession P01579
-
Synonyms HuZAF; Anti-Human IFNG Recombinant Antibody
-
분자량 144.8 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
Human IgG1 kappa
-
Recommend Isotype Controls
-
Format
-
Human IgG1 kappa
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Purity
97.18%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
선적
Shipping with dry ice.
순도&문서
References
[1]. Hommes DW, et al. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut. 2006 Aug;55(8):1131-7. [Content Brief]
[2]. Reinisch W, et al. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. Gut. 2006 Aug;55(8):1138-44. [Content Brief]
[3]. Reinisch W, et al. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflammatory bowel diseases. 2010 Feb;16(2):233-42. [Content Brief]
[5]. Haider AS, et al. Insights into gene modulation by therapeutic TNF and IFNgamma antibodies: TNF regulates IFNgamma production by T cells and TNF-regulated genes linked to psoriasis transcriptome. The Journal of investigative dermatology. 2008 Mar;128(3):655-66. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)